NeuroBloc (botulinum toxin type B)
- Region
- 🇪🇺 EU
- Active substance
- botulinum toxin type B
- Company
- Sloan Pharma S.a.r.l
- Status
- Withdrawn
- Therapeutic area
- Torticollis
- CHMP opinion
- Thu 19 Oct 2000
- EU approval
- Mon 22 Jan 2001
- Application
- EMEA/H/C/000301
- ATC
- M03AX01
- Official record
- www.ema.europa.eu
Indication
NeuroBloc is indicated for the treatment of cervical dystonia (torticollis). See section 5.1 for data on efficacy in patients responsive / resistant to botulinum toxin type A.
Regulatory milestones
No milestones recorded in the last year.
Follow NeuroBloc
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.